

**GLOW LIFETECH CORP.**  
**CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

**GLOW LIFETECH CORP.**  
**CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

**INDEX**

	<b>Page</b>
Independent Auditors' Report	1 - 2
Consolidated Statement of Financial Position	3
Consolidated Statements of Loss and Comprehensive Loss	4
Consolidated Statement of Changes in Equity	5
Consolidated Statement of Cash Flows	6
Notes to the Consolidated Financial Statements	7 - 23

## INDEPENDENT AUDITOR'S REPORT

---

To The Shareholders of Glow LifeTech Corp.

### Opinion

We have audited the consolidated financial statements of Glow LifeTech Corp. which comprise the consolidated statement of financial position as at December 31, 2021, and the consolidated statements of operations and retained earnings and cash flows for the period then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Glow LifeTech Corp. as at December 31, 2021, and the results of its operations and its cash flows for the period then ended in accordance with Canadian International Financial Reporting Standards.

### Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Corporation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Material Uncertainty Related to Going Concerns

We draw attention to Note 1 in the consolidated financial statements, which indicates that the Company is experiencing, and has experienced, negative operating cash flows. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for private enterprises, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Corporation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Corporation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Corporation's financial reporting process.

### Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatements of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether material uncertainty exists related to events or conditions that may cast significant doubt on the Corporation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Corporation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during out audit.

*Jackson & Co., LLP*

April 20, 2022  
Toronto, Ontario

Jackson & Co., LLP  
Chartered Professional Accountants  
Licensed Public Accountants

**GLOW LIFETECH CORP.**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT DECEMBER 31, 2021**

	2021	2020
	\$	\$
<b>CURRENT ASSETS</b>		
Funds held in Trust	122,181	1,800
Bank	746,019	-
Loans and advances receivable	-	799
HST/GST recoverable	260,130	-
Inventory	99,741	-
Prepaid expenses	61,555	-
	1,289,626	2,599
<b>NON-CURRENT ASSETS</b>		
Capital assets (note 5)	393,056	-
Investment in subsidiary (note 8)	1,700,625	-
Intangibles (note 9)	333,333	-
Investment in Nova Mentis Life Science Corp. (note 10)	46,970	-
	2,080,928	-
<b>TOTAL ASSETS</b>	3,763,610	2,599
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued liabilities	175,733	309,172
Loan payable	-	6,400
Due to related companies (note 14)	112,366	-
Equipment loan (note 11)	39,930	-
	328,029	315,572
<b>TOTAL LIABILITIES</b>	328,029	315,572
<b>SHAREHOLDERS' EQUITY (DEFICIT)</b>		
Capital stock (note 12)	11,424,722	25,598,091
Warrant reserve	835,538	-
Contributed surplus	2,489,698	903,452
<b>DEFICIT</b>	(11,314,377)	(26,814,516)
<b>TOTAL SHAREHOLDERS' EQUITY</b>	3,435,581	(312,973)
	3,763,610	2,599
<b>ON BEHALF OF THE BOARD:</b>		
"William Clark Kent"	Director	
"Medhanie Tekeste"	Director	

*The accompanying notes are an integral part of these consolidated financial statements*

**GLOW LIFETECH CORP.**  
**CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS**  
**FOR THE YEAR ENDED DECEMBER 31, 2021**

	2021	2020
	\$	\$
<b>REVENUE</b>	-	-
<b>EXPENSES</b>		
Advertising and promotion	86,727	
Amortization	43,390	
Consulting fees	1,201,843	60,000
Insurance	41,561	-
Interest and bank charges	4,292	-
Loss in investment	57,995	
Management fees	45,000	-
Occupancy costs	156,751	-
Office, general and administrative	44,753	73,300
Professional fees	278,155	20,179
Reverse take-over transaction costs (note 7)	5,974,476	-
Share-based compensation	2,617,921	-
Shareholder communications and marketing	481,688	-
Transfer agent and filing fees	158,140	-
Wage and salary	121,685	-
	11,314,377	153,479
<b>NET LOSS AND COMPREHENSIVE LOSS</b>	<b>(11,314,377)</b>	<b>(153,479)</b>
<b>LOSS PER SHARE</b>		
Basic and diluted	(0.24)	(0.03)
Weighted average number of shares outstanding, basic and diluted	47,690,458	4,666,655

*The accompanying notes are an integral part of these consolidated financial statements*

**GLOW LIFETECH CORP.**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR YEAR ENDED DECEMBER 31, 2021**

	Capital Stock		Warrant Reserve	Contributed Surplus	Deficit	Total
	Number of shares	\$	\$	\$	\$	\$
<b>Balance - January 1, 2020</b>	<b>4,666,655</b>	<b>25,598,091</b>		<b>903,452</b>	<b>(26,661,037)</b>	<b>(159,494)</b>
Net loss for the year					(153,479)	(153,479)
<b>Balance - December 31, 2020</b>	<b>4,666,655</b>	<b>25,598,091</b>		<b>903,452</b>	<b>(26,814,516)</b>	<b>(312,973)</b>
<b>Balance - January 1, 2021</b>	<b>4,666,655</b>	<b>25,598,091</b>		<b>903,452</b>	<b>(26,814,516)</b>	<b>(312,973)</b>
Shares issued pursuant to reverse take-over transaction (notes 7 and 12)	47,334,379	12,073,496	852,966	(903,452)		12,023,010
Shares issued on exercise of options (note 12 (b))	650,000	303,223		(128,223)		175,000
Shares issued on exercise of warrants (note 12 (c))	180,000	89,428	(17,428)			72,000
Share-based compensation (note 12 (b))				2,617,921		2,617,921
Share consolidation (notes 7 and 12)	(4,472,488)					
Reduction in stated capital of common shares (note 12)		(26,814,516)			26,814,516	
Shares issued on settlement of debt (notes 7 and 12)	8,750,000	175,000				175,000
Net loss for the year					(11,314,377)	(11,314,377)
<b>Balance - December 31, 2021</b>	<b>57,108,546</b>	<b>11,424,722</b>	<b>835,538</b>	<b>2,489,698</b>	<b>(11,314,377)</b>	<b>3,435,581</b>

*The accompanying notes are an integral part of these consolidated financial statements*

**GLOW LIFETECH CORP.**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED DECEMBER 31, 2021**

	2021	2020
	\$	\$
<b>CASH PROVIDED BY (USED IN):</b>		
<b>OPERATING ACTIVITIES</b>		
Net loss and comprehensive loss for the period	(11,314,377)	(153,479)
Items not involving cash		
Depreciation - tangible assets	43,390	-
Loss in investment	57,995	-
Stock-based compensation	2,617,921	-
Reverse take-over transaction costs	5,974,476	-
	(2,620,595)	(153,479)
Changes in non-cash working capital items		
Decrease (increase) in loan and advances receivable	799	(691)
(Increase) in HST/GST recoverable	(260,130)	-
Increase in inventory	(99,741)	-
Increase in prepaid expenses	(61,555)	-
(Decrease) increase in accounts payable and accrued liabilities	(133,439)	135,518
Decrease in loan payable	(6,400)	-
	(3,181,061)	(18,652)
<b>INVESTING ACTIVITIES</b>		
Investment in Nova Mentis Life Science Corp.	(104,965)	-
Purchase of capital assets	(436,446)	-
	(541,411)	-
<b>FINANCING ACTIVITIES</b>		
Glow Ltd. cash on hand and non-cash working capital at March 3, 2021	945,614	-
Investment in Swiss Pharmacan Corp. at March 3, 2021	(1,700,625)	-
Intangibles at March 3, 2021	(333,333)	-
Increase in equipment loan	39,930	-
Advances from related parties	112,366	-
Proceeds from options exercise	175,000	-
Proceeds from warrant exercise	72,000	-
Proceeds from private placement, net of issue costs	5,277,920	-
	4,588,872	-
<b>NET INCREASE (DECREASE) IN CASH FOR THE PERIOD</b>	866,400	(18,652)
<b>CASH, beginning of period</b>	1,800	20,452
<b>CASH, end of period</b>	868,200	1,800
<b>REPRESENTED BY:</b>		
Funds held in Trust	122,181	1,800
Bank	746,019	-
	868,200	1,800

*The accompanying notes are an integral part of these consolidated financial statements*



**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

---

**1. NATURE OF OPERATIONS AND GOING CONCERN**

Glow Lifetech Corp., formerly Ateba Resources Inc., (the "Company" or "Glow") was formed under the laws of the Province of Ontario on February 1, 1988. The Company was primarily engaged in the acquisition and exploration of mineral properties in Canada.

Glow LifeTech Ltd. ("Glow Ltd.") was incorporated in Ontario on December 17, 2018 as 2671237 Ontario Ltd. and on February 6, 2019 filed Articles of Amendment changing its name to Glow LifeTech Ltd. Glow Ltd. is engaged in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility.

On March 3, 2021, Glow Ltd. completed a business combination pursuant to the terms of a Business Combination Agreement dated June 24, 2020 (the "Business Combination Agreement") amongst Glow Ltd., Ateba Resources Inc. ("Ateba") and the shareholders of Glow Ltd. by way of three-cornered amalgamation. On June 15, 2021 2760626 Ontario Inc. was incorporated ("subco") which is a wholly-owned subsidiary of Ateba solely for the purpose of completing the Amalgamation with Glow Ltd., which was completed on March 3, 2021. Pursuant to the Business Combination Agreement, Ateba issued 47,334,379 common shares to the Glow Ltd. shareholders, representing approximately 84.1% of the issued share capital of Ateba on the closing date of the transaction. On February 26, 2020, Ateba pursuant to the terms of the transaction changed its name to Glow Lifetech Corp.

The principal business address of the Company is 65 International Blvd. Suite 202, Toronto, Ontario M9W 6L9.

The Company's ability to continue as a going concern is dependent upon the need to both manage expenditures and to raise additional funds. The Company is experiencing, and has experienced, negative operating cash flows and has working capital of \$961,597 as at December 31, 2021 ( December 31, 2020a working capital deficiency of \$312,973). The Company will continue to search for new or alternate sources of financing in order to continue development of its products. These material uncertainties cast significant doubt on the Company's ability to continue as a going concern.

There can be no assurance that the Company will be able to continue to raise funds when required in which case the Company may be unable to meet its obligations. Should the Company be unable to realize on its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded on the statement of financial position.

**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

---

**2. BASIS OF PRESENTATION**

These consolidated financial statements include the accounts of Glow Lifetech Ltd., a wholly owned subsidiary acquired by the Company on March 3, 2021 and Swiss Pharma Corp., a wholly owned Canadian subsidiary of Glow Lifetech Ltd., acquired by the company on June 10, 2020.

**Statement of Compliance**

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

**Basis of Measurement**

These consolidated financial statements have been prepared on the historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

**Functional and Presentation Currency**

The consolidated financial statements are presented in Canadian dollars, which is also the Company's functional currency.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The following accounting policies have been applied consistently to all periods presented in these consolidated financial statements:

**(a) IMPAIRMENT**

At each financial position reporting date, the carrying amounts of the Company's long-lived assets are reviewed to determine whether there is any indication that those assets are impaired at a cash generating unit level. If any such indication exists, the recoverable amount of the cash generating unit is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use, which is the present value of future cash flows expected to be derived. If the recoverable amount is estimated to be less than its carrying amount, the carrying amount is reduced to its recoverable amount and the impairment loss is recognized in the profit or loss for the period.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

#### **(b) INTANGIBLE ASSETS**

The Company records intangible assets at fair value at the date of acquisition. An intangible asset is capitalized when the economic benefit associated with an asset is probable and when the cost can be measured reliably. Intangible assets are carried at cost less accumulated depreciation and impairment losses. Cost consists of expenditures directly attributable to the acquisition of the assets. Intangible assets with finite lives are amortized over the related benefit period. Those with indefinite lives are not amortized and are tested for impairment on an annual basis. The Company's intangible assets consist of patents, patent applications and research and development costs that are amortized over their five-year estimated useful life commencing with their utilization in revenue generating activities.

#### **(c) RESEARCH AND DEVELOPMENT COSTS**

Costs associated with the development of the Company's products are capitalized where the following criteria are met:

- the technical feasibility of completing the intangible asset so it will be available for use or sale;
- its intention to complete and its ability to use or sell the assets;
- how the asset will generate future economic benefits;
- the availability of resources to complete the asset; and
- the ability to measure reliably of the expenditure during development.

In the prior year the Company acquired a research and development project which was capitalized and included in intangibles. The Company did not incur other research and development costs in the period.

#### **(d) SHARE-BASED PAYMENTS**

The Company accounts for share-based payments using the fair value method. Under this method, employee stock options recognized as compensation expense are measured at fair value on the date of grant using the Black Scholes option pricing model, and are recognized as an expense or capitalized, depending on the nature of the grant, with a corresponding increase in equity, over the period that the employees earn the options. The amount recognized as an expense is adjusted to reflect the number of share options expected to vest. The Black Scholes option pricing model requires the input of subjective assumptions, including the expected term of the option and stock price volatility.

For transactions with employees and others providing similar services, the Company measures the fair value of the services received by reference to the fair value of the services rendered. For transactions with parties other than employees, the Company measures the goods or services received, and the corresponding increase in equity, directly, at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. When the Company cannot estimate reliably the fair value of the goods or services received, it measures their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted.

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

#### (e) FOREIGN CURRENCY TRANSLATION

The Company's functional and presentation currency is the Canadian dollar. Foreign currency transactions are initially recorded in the functional currency at the transaction date exchange rate. At closing date, monetary assets and liabilities denominated in a foreign currency are translated into the functional currency at the closing date exchange rate, and non-monetary assets and liabilities at the historical rates. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in profit or loss.

#### (f) FINANCIAL INSTRUMENTS

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument.

Under IFRS 9, financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows. IFRS 9 contains the primary measurement categories for financial assets: measured at amortized cost, fair value through other comprehensive income ("FVTOCI") and fair value through profit and loss ("FVTPL").

Below is a summary showing the classification and measurement bases of financial instruments;

Asset or Liability	Category	Measurement
Cash and funds held in trust	FVTPL	Fair value
Accounts payable and accrued liabilities	Other liabilities	Amortized cost
Loans and advances	Current assets	Fair value
Related party receivables	Current assets	Fair Value

#### *Financial assets*

Financial assets are classified as either financial assets at FVTPL, amortized cost, or FVTOCI. The Company determines the classification of its financial assets at initial recognition.

- (i) Financial assets recorded at FVTPL  
Financial assets are classified as FVTPL if they do not meet the criteria of amortized cost or FVTOCI. Gains or losses on these items are recognized in profit or loss. The Company's cash and cash equivalents and marketable securities are classified as financial assets measured at FVTPL.
- (ii) Amortized cost  
Financial assets are classified as measured at amortized cost if both of the following criteria are met and the financial assets are not designated as at FVTPL: 1) the object of the Company's business model for these financial assets is to collect their contractual cash flows; and 2) the asset's contractual

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

cash flows represent "solely payments of principal and interest". The Company's loan receivable is classified as financial assets measured at amortized cost.

#### *Financial liabilities*

Financial liabilities are classified as either financial liabilities at FVTPL or at amortized cost. The Company determines the classification of its financial liabilities at initial recognition.

(i) Amortized cost

Financial liabilities are classified as measured at amortized cost unless they fall into one of the following categories: financial liabilities at FVTPL, financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition, financial guarantee contracts, commitments to provide a loan at a below-market interest rate, or contingent consideration recognized by an acquirer in a business combination.

The Company's accounts payable and accrued liabilities and Due to shareholders do not fall into any of the exemptions and are therefore classified as measured at amortized cost.

(ii) Financial liabilities recorded FVTPL

Financial liabilities are classified as FVTPL if they fall into one of the five exemptions detailed above.

#### *Transaction costs*

Transaction costs associated with financial instruments, carried at FVTPL, are expensed as incurred, while transaction costs associated with all other financial instruments are included in the initial carrying amount of the asset or the liability.

#### *Subsequent measurement*

Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in profit or loss. Instruments classified as amortized cost are measured at amortized cost using the effective interest rate method. Instruments classified as FVTOCI are measured at fair value with unrealized gains and losses recognized in other comprehensive income.

#### *Derecognition*

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

#### *Expected credit loss impairment model*

IFRS 9 introduced a single expected credit loss impairment model, which is based on changes in credit quality since initial application. The adoption of the expected credit loss impairment model had no impact on the Company's consolidated financial statements.

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due. The Company considers a financial asset to be in default when the borrower is unlikely to pay its credit obligations to the Company in full or when the financial asset is more than 90 days past due.

The carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off.

#### *Financial instruments at fair value through profit and loss*

Financial instruments recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 – valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Cash and funds held in trust are measured at fair value using Level 1 inputs.

As at December 31, 2021 and December 31, 2020, the fair value of the financial liabilities approximates the carrying value, due to the short-term nature of the instruments.

#### **(g) REVENUE RECOGNITION**

Product sales revenue is recognized when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is recognized on a time-proportion basis using the effective interest method.

#### **(h) FUNDS HELD IN TRUST**

Funds held in trust consists of cash on hand, deposits in banks and funds held in trust by the Company's external legal counsel. Funds held in trust are not restricted and can be used for working capital purposes.

#### **(i) PROPERTY, PLANT AND EQUIPMENT**

Property, plant and equipment is stated at historical cost less accumulated depreciation and accumulated impairment losses.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

charged to the statement of loss and comprehensive loss during the financial period in which they are incurred.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in profit or loss in the period.

Amortization is calculated on a straight line basis at the following annual rates:

Laboratory and technical equipment	3 years
Office, furniture and equipment	3 years
Computer equipment	2 years

#### **(j) INCOME TAXES**

Income tax on profit or loss for the year comprises of current and deferred tax. Current tax is the expected tax paid or payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax paid or payable in respect of previous years.

Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized. The effect on deferred income tax assets and liabilities of a change in income tax rates is recognized in the period that includes the date of the enactment or substantive enactment of the change. Deferred tax assets and liabilities are presented separately except where there is a right of set off within fiscal jurisdictions.

#### **(k) COMPREHENSIVE INCOME (LOSS)**

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss) and represents the change in shareholders' equity which results from transactions and events from sources other than the Company's shareholders. Income or loss from an investment in associate is included in other comprehensive income (loss). Accumulated other comprehensive income (net of income taxes) is included on the consolidated statements of financial position as a component of common shareholders' equity.

#### **4. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES**

The preparation of these consolidated financial statements in conformity with IFRS requires that management make estimates and assumptions about future events that affect the amounts reported in the consolidated financial statements and related notes to the interim non-consolidated financial statements. Actual results may differ from those estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

---

(i) Critical accounting estimates

Critical accounting estimates are estimates and assumptions made by management that may result in a material adjustment to the carrying amount of assets and liabilities within the next financial year and are, but are not limited to, the following:

*Share based payments and warrants*

The fair value of stock options and warrants issued are subject to the limitation of the Black Scholes option pricing model that incorporates market data and involves uncertainty in estimates used by management in the assumptions. Because the Black Scholes option pricing model requires the input of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate.

*Useful life of intangible assets*

Management has exercised their judgment in determining the useful life of its patents, patent applications and research and development costs. The estimate is based on the expected period of benefit of the patent and the expected life of the product in the market place.

(ii) Critical accounting judgments

Information about critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are, but are not limited to, the following:

*Determination of functional currency*

In accordance with IAS 21, The Effects of Changes in Foreign Exchange Rates, management has determined that the functional currency of the Company is the Canadian dollar.

*Evaluation of going concern*

The preparation of the consolidated financial statements requires management to make judgments regarding the going concern of the Company as previously discussed in Note 1.

*Impairment of intangible assets*

Management has exercised their judgment in determining if the patents are impaired. The judgment is based on the expected future benefit of the intangible assets.

*Income taxes*

Management has exercised their judgment in determining the provision for future income taxes. The judgment is based on the Company's current understanding of the tax law as it relates to the transactions and activities entered into by the Company.



**GLOW LIFETECH CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2021**

**5. CAPITAL ASSETS**

Amounts payable and amounts receivable from related parties, are non-interest bearing, unsecured and have no specific terms of repayment.

	<b>Laboratory equipment</b>	<b>Office furniture &amp; equipment</b>	<b>Computer equipment</b>	<b>Total</b>
	\$	\$	\$	\$
<b>Cost</b>				
As at December 31, 2019	-	-	-	-
Additions	-	-	-	-
<b>As at December 31, 2020</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Additions	294,387	137,981	4,078	436,446
<b>As at December 31, 2021</b>	<b>294,387</b>	<b>137,981</b>	<b>4,078</b>	<b>436,446</b>
<b>Accumulated amortization</b>				
As at December 31, 2019	-	-	-	-
Amortization for the period	-	-	-	-
<b>As at December 31, 2020</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Amortization for the period	29,439	13,798	153	43,390
<b>As at December 31, 2021</b>	<b>29,439</b>	<b>13,798</b>	<b>153</b>	<b>43,390</b>
<b>Net book value</b>				
As at December 31, 2019	-	-	-	-
<b>As at December 31, 2020</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>As at December 31, 2021</b>	<b>264,948</b>	<b>124,183</b>	<b>3,925</b>	<b>393,056</b>

**6. MANUFACTURING PARTNERSHIP**

Glow has entered a collaborative partnership with a Health Canada licensed producer ("MEDZ") for cannabis product manufacturing. Glow will perform manufacturing services within a dedicated facility under the quality and compliance control of MEDZ. Glow will operate its own equipment as a contractor of MEDZ, but all products are released under MEDZ license. The Company has completed the build out of this manufacturing facility.

**7. REVERSE TAKE-OVER TRANSACTION**

On March 3, 2021, the company completed a transaction pursuant to the terms of a Business Combination Agreement dated June 24, 2020 between with the Company and Glow Lifetech Ltd ("Glow Ltd.").

Pursuant to the Business Combination Agreement, the Company issued an aggregate of 47,334,379 common shares (the "Consideration Shares") of the Company to the former Glow Ltd. shareholders (the "Glow Shareholders"), such that upon completion of the Transaction the former Glow Shareholders hold approximately 84% of the total number of the issued and outstanding common shares in the capital of the Company. All outstanding unexercised warrants in the capital of Glow Ltd. (the "Glow Warrants") to acquire common

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

shares in the capital of Glow were cancelled. In consideration for such disposition, the holders of the Glow Warrants received replacement warrants (the "Replacement Warrants"), to acquire one post-consolidation common share in the capital of the Company (each, a "Common Shares"), such Replacement Warrants bearing the same terms and conditions as the Glow Warrants. The board of directors of the Company was reconstituted in conjunction with the completion of the Transaction.

In connection with the Transaction, Glow Ltd. completed a nonbrokered private placement financing of 17,778,429 units of Glow Ltd. (the "Units") at a price of \$0.30 per Unit for gross proceeds of \$5,336,530 and net proceeds after accounting for share issuance costs of \$5,277,920. Each Unit is comprised of one common share in the capital of Glow Ltd. (each, a "Unit Share") and one-half of one whole common share purchase warrant (each whole warrant, a "Warrant") exercisable at a price of \$0.40 per common share (each a "Warrant Share") for a period of two years from the date of issuance.

Prior to the completion of the Transaction, the Company settled an aggregate of \$175,000 of indebtedness owed to an arm's length creditor through the issuance of 8,750,000 pre-consolidation common shares of the Company at a price of \$0.02 per common share (the "Debt Settlement"). All Common Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

Prior to the completion of the Transaction, the Company changed its name from "Ateba Resources Inc." to its current name, "Glow LifeTech Corp." in accordance with the provisions of the Business Corporations Act (Ontario). Also prior to the completion of the Transaction, the Company consolidated its common shares on the basis of one and one-half (1.5) pre-consolidation common shares for one (1) post-consolidation common share.

The substance of the transaction is a reverse take-over of a non-operating company. The transaction does not constitute a business combination, as the the Company, prior to March 3, 2021 did not meet the definition of a business under IFRS 3, Business Combination. As a result, the transaction has been accounted for as a capital transaction with Glow Lifetech Ltd. being identified as the acquirer and the equity consideration accounted for in accordance with IFRS 2, Share-based Payment, measured at fair value.

The fair value of the consideration paid of \$5,909,190 has been allocated as follows:

	\$
Cash	1,226
Accounts receivable	255
Accounts payable	(44,230)
Accrued liabilities	(12,000)
Other current liabilities	(10,537)
<u>Net liabilities assumed</u>	<u>(65,286)</u>
Transaction costs	5,974,476
<u>Fair value of consideration paid</u>	<u>5,909,190</u>

**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

---

**8. INVESTMENT IN SUBSIDIARY**

On October 3, 2019, Glow Ltd. signed a binding letter of intent (the LOI) with Swiss PharmaCan AG / Micelle Technologies AG / Mivital (collectively SMM) to acquire a 100% interest in Swiss Pharma Corp. (SPC) and to establish an international joint-venture partnership to advance the business plan of SPC. SMM is in the business of developing and producing micellized materials including cannabis for medical, supplemental and recreational use and under the terms of the LOI has granted exclusive license to certain intellectual property of SMM, consisting of cannabis related formulations, iron formulations, curcumin formulations and vitamin K formulations to SPC.

On June 1, 2020 Glow Ltd. entered into a Share Exchange Agreement (the Agreement) between Glow Ltd., Swiss Pharmacan AG and Swiss Pharma Corp., whereby Glow Ltd. acquired all of the issued and outstanding shares of Swiss Pharma Corp. from Swiss Pharmacan AG for the aggregate purchase price of CAD\$6,000,000. The net assets held by Swiss Pharma Corp. consist primarily of an Exclusive Licence Agreement dated January 7, 2020 between Swiss Pharma Corp. and Swiss Pharmacan AG as described in Note 9. As Swiss Pharma Corp. did not meet the definition of a business under IFRS 3, the acquisition has been accounted for as an asset acquisition whereby Glow Ltd. is considered to acquire the net assets of Swiss Pharma Corp. at their fair market value, with the total purchase price attributed to the fair market value of Swiss Pharma Corp.'s Exclusive Licence Agreement.

The purchase price of CAD\$6,000,000 is to be satisfied as follows:

- (i) an initial payment of CHF\$250,000, such payment being made on the signing of the binding Letter of Intent which was paid on October 3, 2019;
- (ii) an additional payment of CHF\$250,000 payable on or before 90 days following the execution of the Agreement which was paid on July 16, 2020;
- (iii) the issuance to Swiss Pharmacan AG of an aggregate 30,000,000 shares of the Company as fully paid and non-assessable, at a deemed price equal to CAD\$0.20 per share in accordance with the following schedule of deliverables by Swiss Pharmacan AG:
  - a. 5,000,000 shares issued to Swiss Pharmacan AG upon execution of the agreement which were issues on June 1, 2020;
  - b. an additional 10,000,000 shares issued to Swiss Pharmacan AG upon the transfer to and receipt by the Company of reactor documentation, operating protocols and other relevant know-how to allow the Company to commercialise the Intellectual Property pursuant to a Licence Agreement dated January 7, 2020 between Swiss Pharma Corp. and Swiss Pharmacan AG;

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

---

- c. an additional 5,000,000 shares issued to Swiss Pharmacan AG upon successful completion of the first bio-reactor build and transport of the machine to the facilities of the Company and successful set-up at the Company's facilities;
- d. an additional 5,000,000 shares issued to Swiss Pharmacan AG upon successful testing of the bio-reactor at the Company's facilities, to the Company's satisfaction;
- e. an additional 2,000,000 shares issued to Swiss Pharmacan AG at the time of the first commercial shipment of products processed using the bio-reactor; and,
- f. an additional 3,000,000 shares issued to Swiss Pharmacan AG upon receipt to the Company of CAD\$10,000,000 in gross revenues through the direct commercialisation of the Intellectual Property as contemplated by the Licence Agreement.

As this acquisition is to be completed in stages as described above, with specific actions required to complete each stage, the acquisition of and valuation of the net assets acquired is being accounted for as a series of contracts, with recognition of each stage at such time that relative certainty exists that each stage's requirements have been satisfied.

#### 9. INTANGIBLES

On April 3, 2019, Glow Ltd. purchased from Relay Medical Corp. a suite of technology assets for 6,250,000 common shares valued at \$333,333. The assets purchased include copyright and trade names, provisional IP, trade secrets, user trial methodologies, supply chain agreements, prototypes, software and toolkits.

The net intangible assets of \$1,700,625 held by Swiss Pharma Corp. consist primarily of an Exclusive Licence Agreement dated January 7, 2020 between Swiss Pharma Corp. and Swiss Pharmacan AG for the use by Swiss Pharma Corp. of Swiss Pharmacan AG's technology including Intellectual Property, Patents and the Know-how, including any improvements, to develop its business for certain cannabis and nutraceutical products in Canada, the United States and Mexico.

#### 10. INVESTMENT IN NOVA MENTIS LIFE SCIENCE CORP

The Company invested a minority stake in Nova Mentis Life Science Corp. ("Nova") by purchasing 854,000 of the outstanding shares in the open market for a total of \$104,965 or \$0.1229 per common share.

At December 31, 2021 the the shares of Nova closed at a price of \$0.055 per common share, resulting in the Company recording a loss in it's investment in Nova of \$57,995.

# GLOW LIFETECH CORP.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

Nova aims to develop psilocybin-based therapies for the treatment of Autism Spectrum Disorder (“Autism” or “ASD”) and Fragile X Syndrome (“FXS”). Nova will also aim to recruit participants across the U.S and Canada for its large-scale observational study to assess the gut microbiome, immune response, and serotonin activity, as all these systems are likely involved in producing the variety of gut and behavioural symptoms observed in Autism and FXS.

### 11. EQUIPMENT LOAN

On April 23, 2021 the Company entered into an agreement to purchase laboratory equipment. The agreement provides for 12 monthly payments of \$6,242 USD or \$74,904 USD. The Company's initial payment on signing was \$25,979 (\$20,676 USD). Payments commenced May 1, 2021. As of December 31, 2021, the company has paid \$58,426 (\$45,644 US) of which \$1,435 has been recorded as interest expense.

### 12. CAPITAL STOCK

#### (a) Common shares

##### Authorized

The authorized capital stock of the Company consists of an unlimited number of common shares.

##### Issued and Outstanding

	#	\$
Balance December 31, 2019 and 2020	4,666,655	25,598,091
Balance January 1, 2021	4,666,655	25,598,091
Debt settlement (i)	8,750,000	175,000
Share consolidation 1.5:1 (ii)	(4,472,488)	-
Stated capital reduction (iii)	-	(26,814,516)
Reverse take-over transaction (note 7)	29,545,950	6,795,576
Shares issued on private placement (note 7)	17,788,429	5,277,920
Shares issued on exercise of options (iv)	650,000	303,223
Shares issued on exercise of warrants (v)	180,000	89,428
Balance December 31, 2021	57,108,546	11,424,722

- (i) on March 3, 2021, the Company issued 8,750,000 common shares for the settlement of a \$175,000 debt owed by the Company at a price of \$0.02 per common share;
- (ii) immediately prior to the completion of the reverse take-over transaction (note 7), the shareholders approved a share consolidation, issuing 1 common share for 1.5 common shares outstanding;
- (iii) immediately prior to the completion of the reverse take-over transaction (note 7), the shareholders approved a reduction in the stated capital of the Company in the amount of \$26,814,516;

## GLOW LIFETECH CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021

- (iv) during the year-ended December 31, 2021, 650,000 common shares were issued in connection with the exercise of 650,000 stock options at an exercise price of \$0.27 for gross proceeds of \$175,000;
- (v) on April 30, 2021, 180,000 common shares were issued at a price of \$0.40 per common share in connection with the exercise of 180,000 warrants for gross proceeds of \$72,000;

#### (b) Stock option plan and share-based compensation

The Company has a stock option plan under which it is authorized to grant options to directors, employees and consultants enabling them to acquire up to 20% of the issued and outstanding common shares of the Company. Under the plan, the exercise price of each option equals the market price, minimum price, or a discounted price of the Company's shares as calculated on the date of grant.

	Number of Options Outstanding	Black Scholes Value \$	Weighted Average Exercise Price \$
Balance December 31, 2020	-	-	-
Granted	11,510,000	2,617,921	0.30
Exercised	650,000	128,223	0.27
Balance December 31, 2021	10,860,000	2,489,698	0.30

On March 3, 2021, the Company announced that it has granted an aggregate of 10,800,000 options to purchase common shares of the company with an estimated fair value of \$2,476,128 exercisable at a price of \$0.30 per common share, vesting immediately and expiring March 4, 2026 to certain directors, officers and consultants of the Company.

On May 28, 2021, the Company also issued 210,000 options with an estimated fair value of \$53,161 exercisable at a price of \$0.34 per common share, vesting immediately and expiring May 28, 2026 to certain officers and consultants of the Company.

On October 14, 2021, the Company also issued 500,000 options with an estimated fair value of \$88,632 exercisable at a price of \$0.25 per common share, vesting immediately and expiring October 14, 2026 to certain officers and consultants of the Company.

**GLOW LIFETECH CORP.**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2021**

The following common share purchase options are outstanding as at December 31, 2021:

Date of Grant	Number of Outstanding Options	Exercise Price \$	Weighted Average Remaining Life (years)	Expiry Date	Number of Options Exercisable
March 3, 2021	10,550,000	0.30	4.17	March 4, 2026	10,550,000
May 28, 2021	210,000	0.34	4.41	May 28, 2026	210,000
October 14, 2021	100,000	0.25	4.79	October 14, 2026	100,000
	10,860,000		4.18		10,860,000

The fair value of options granted during the was estimated at the date of grant using a Black Scholes Option Pricing Model with the following assumptions:

	March 3, 2021	May 28, 2021	October 14, 2021
Share price	\$ 0.30	\$ 0.34	\$ 0.25
Risk-free interest rate	0.70 %	0.75 %	1.07 %
Expected life of options	5 years	5 years	5 years

**(c) Warrants**

The following table summarizes warrants that have been issued, exercised, or have expired during the quarter ended December 31, 2021:

	Number of Options Outstanding	Black Scholes Value \$	Weighted Average Exercise Price \$
Balance December 31, 2020	-	-	-
Granted	8,809,838	852,966	0.40
Exercised	180,000	17,428	0.40
Balance December 31, 2021	8,629,838	835,538	0.40

The fair value of warrants granted was estimated at the date of grant using a Black Scholes Option Pricing Model with the following assumptions:

	March 3, 2021
Share price	\$ 0.30
Risk-free interest rate	0.26 %
Time to maturity (years)	1.5
Expected life of options	5 years

**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

As at December 31, 2021, the following warrants were outstanding. The warrants entitle the holders to purchase the stated number of common shares at the exercise price on or before the expiry date:

Date of Grant	Number of Warrants Outstanding	Exercise Price \$	Fair Value \$	Expiry Date
March 3, 2021	-	-	-	August 11, 2022
April 1, 2021	8,629,838	0.40	835,538	September 2, 2022
	8,629,838		835,538	

**13. RELATED PARTY TRANSACTIONS**

During the year the company paid managements fees of \$45,000 and rent of \$35,724 to Scryb Inc., a shareholder of the company.

These transactions are in the normal course of operations.

**14. DUE TO AND FROM RELATED PARTIES**

Amounts payable and amounts receivable from related parties, are non-interest bearing, unsecured and have no specific terms of repayment.

**15. FINANCIAL RISK FACTORS**

The Company manages its exposure to a number of different financial risks arising from its operations as well as its use of financial instruments including market risks, credit risk and liquidity risk through its risk management strategy. The objective of the strategy is to support the delivery of the Company's financial targets while protecting its future financial security and flexibility.

Financial risks are primarily managed and monitored through operating and financing activities and, if required. The financial risks are evaluated regularly with due consideration to changes in the key economic indicators and up-to-date market information.

The Company's financial instruments primarily consist of cash. The fair value of the Company's accounts payable and accrued liabilities approximate their carrying value, due to their short-term maturities or ability of prompt liquidation.

The Company's cash is recorded at fair value, under the fair value hierarchy, based on level one quoted prices in active markets for identical assets of liabilities. The Company is exposed in varying degrees to a variety of financial instrument related risks.



**GLOW LIFETECH CORP.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2021**

---

**Market Risk**

Market risk is the risk or uncertainty arising from possible market price movements and their impact on the future performance of the business. These market risks are evaluated by monitoring changes in key economic indicators and market information on an on-going basis.

(i) Interest Rate Risk

The Company has cash balances and is not at a significant risk to fluctuating interest rates. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. The Company monitors the credit worthiness of the debtor and is satisfied with the debtor's ability to repay the amount owing.

(ii) Foreign currency risk

As at December 31, 2021 the Company's expenditures are predominantly in Canadian dollars, and any future equity raised is expected to be predominantly in Canadian dollars and therefore is not at a significant risk to fluctuating exchange risks.

**Liquidity Risk**

Liquidity risk encompasses the risk that a company cannot meet its financial obligations in full. The Company's main source of liquidity is derived from its common stock issuances. These funds are primarily used to finance working capital, operating expenses, capital expenditures, and acquisitions.

The Company manages its liquidity risk by regularly monitoring its cash flows from operating activities and holding adequate amounts of cash and cash equivalents. As at December 31, 2021 the Company held cash in banks and cash in trust of \$868,200 (December 31, 2020 - \$1,800) to settle current liabilities of \$328,029 (December 31, 2020 - \$315,572).

**Credit Risk**

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist of cash. The Company has reduced its credit risk by investing its cash in trust with Canadian chartered banks.